161 related articles for article (PubMed ID: 33290354)
21. High-grade Serous Carcinoma can Show Squamoid Morphology Mimicking True Squamous Differentiation.
Tomonobe H; Ohishi Y; Hachisuga K; Yahata H; Kato K; Oda Y
Am J Surg Pathol; 2023 Sep; 47(9):967-976. PubMed ID: 37382102
[TBL] [Abstract][Full Text] [Related]
22. TP53 as a Diagnostic Aid in the Distinction of Ovarian Mucinous Borderline Tumors From Mucinous Carcinoma.
Kang EY; Terzic T; Ghatage P; Woo L; Gorringe KL; Karnezis AN; Lee CH; Köbel M
Int J Gynecol Pathol; 2024 Mar; 43(2):111-122. PubMed ID: 37406453
[TBL] [Abstract][Full Text] [Related]
23. The fading guardian: clinical relevance of TP53 null mutation in high-grade serous ovarian cancers.
Biatta CM; Paudice M; Greppi M; Parrella V; Parodi A; De Luca G; Cerruti GM; Mammoliti S; Caroti C; Menichini P; Fronza G; Pesce S; Marcenaro E; Vellone VG
Front Immunol; 2023; 14():1221605. PubMed ID: 37680633
[TBL] [Abstract][Full Text] [Related]
24. The Prognostic Effect of Immune Cell Infiltration Depends on Molecular Subtype in Endometrioid Ovarian Carcinomas.
Heinze K; Cairns ES; Thornton S; Harris B; Milne K; Grube M; Meyer C; Karnezis AN; Fereday S; Garsed DW; Leung SCY; Chiu DS; Moubarak M; Harter P; Heitz F; McAlpine JN; DeFazio A; Bowtell DDL; Goode EL; Pike M; Ramus SJ; Pearce CL; Staebler A; Köbel M; Kommoss S; Talhouk A; Nelson BH; Anglesio MS
Clin Cancer Res; 2023 Sep; 29(17):3471-3483. PubMed ID: 37339172
[TBL] [Abstract][Full Text] [Related]
25. Insights into endometrial serous carcinogenesis and progression.
Fadare O; Zheng W
Int J Clin Exp Pathol; 2009; 2(5):411-32. PubMed ID: 19294001
[TBL] [Abstract][Full Text] [Related]
26. Accurate interpretation of p53 immunohistochemical patterns is a surrogate biomarker for TP53 alterations in large B-cell lymphoma.
Li X; Luo D; Zhang L; Li Q; Fan J; Zhang J; Huang B; Yang M; Nie X; Chang X; Pan H
BMC Cancer; 2023 Oct; 23(1):1008. PubMed ID: 37858047
[TBL] [Abstract][Full Text] [Related]
27. Endometrial carcinoma: 10 years of TCGA (the cancer genome atlas): A critical reappraisal with comments on FIGO 2023 staging.
Espinosa I; D'Angelo E; Prat J
Gynecol Oncol; 2024 Apr; 186():94-103. PubMed ID: 38615479
[TBL] [Abstract][Full Text] [Related]
28. The pattern-based interpretation of p53 immunohistochemical expression as a surrogate marker for TP53 mutations in colorectal cancer.
Osakabe M; Yamada N; Sugimoto R; Uesugi N; Nakao E; Honda M; Yanagawa N; Sugai T
Virchows Arch; 2024 Mar; ():. PubMed ID: 38512505
[TBL] [Abstract][Full Text] [Related]
29. Amyloid-like p53 as prognostic biomarker in serous ovarian cancer-a study of the OVCAD consortium.
Heinzl N; Maritschnegg E; Koziel K; Schilhart-Wallisch C; Heinze G; Yang WL; Bast RC; Sehouli J; Braicu EI; Vergote I; Van Gorp T; Mahner S; Paspalj V; Grimm C; Obermayr E; Schuster E; Holzer B; Rousseau F; Schymkowitz J; Concin N; Zeillinger R
Oncogene; 2023 Aug; 42(33):2473-2484. PubMed ID: 37402882
[TBL] [Abstract][Full Text] [Related]
30. Molecular pathogenesis of endometrial and ovarian cancer.
Merritt MA; Cramer DW
Cancer Biomark; 2010; 9(1-6):287-305. PubMed ID: 22112481
[TBL] [Abstract][Full Text] [Related]
31. Implication of cytoplasmic p53 expression in pulmonary neuroendocrine carcinoma using next-generation sequencing analysis.
Jimbo N; Ohbayashi C; Fujii T; Takeda M; Mitsui S; Tsukamoto R; Tanaka Y; Itoh T; Maniwa Y
Histopathology; 2024 Jan; 84(2):336-342. PubMed ID: 37814580
[TBL] [Abstract][Full Text] [Related]
32. P53 in Penile Squamous Cell Carcinoma: A Pattern-Based Immunohistochemical Framework with Molecular Correlation.
Trias I; Saco A; Marimon L; López Del Campo R; Manzotti C; Ordi O; Del Pino M; Pérez FM; Vega N; Alós S; Martínez A; Rodriguez-Carunchio L; Reig O; Jares P; Teixido C; Ajami T; Corral-Molina JM; Algaba F; Ribal MJ; Ribera-Cortada I; Rakislova N
Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345055
[TBL] [Abstract][Full Text] [Related]
33. Immunohistochemical correlates of TP53 somatic mutations in cancer.
Murnyák B; Hortobágyi T
Oncotarget; 2016 Oct; 7(40):64910-64920. PubMed ID: 27626311
[TBL] [Abstract][Full Text] [Related]
34. Uterine Carcinomas in Tetrabromobisphenol A-exposed Wistar Han Rats Harbor Increased Tp53 Mutations and Mimic High-grade Type I Endometrial Carcinomas in Women.
Harvey JB; Osborne TS; Hong HH; Bhusari S; Ton TV; Pandiri AR; Masinde T; Dunnick J; Peddada S; Elmore S; Hoenerhoff MJ
Toxicol Pathol; 2015 Dec; 43(8):1103-13. PubMed ID: 26353976
[TBL] [Abstract][Full Text] [Related]
35. Temporal dissection of tumorigenesis in primary cancers.
Durinck S; Ho C; Wang NJ; Liao W; Jakkula LR; Collisson EA; Pons J; Chan SW; Lam ET; Chu C; Park K; Hong SW; Hur JS; Huh N; Neuhaus IM; Yu SS; Grekin RC; Mauro TM; Cleaver JE; Kwok PY; LeBoit PE; Getz G; Cibulskis K; Aster JC; Huang H; Purdom E; Li J; Bolund L; Arron ST; Gray JW; Spellman PT; Cho RJ
Cancer Discov; 2011 Jul; 1(2):137-43. PubMed ID: 21984974
[TBL] [Abstract][Full Text] [Related]
36. Practical Updates and Diagnostic Challenges in Endometrial Carcinoma.
Turashvili G; Hanley K
Arch Pathol Lab Med; 2024 Jan; 148(1):78-98. PubMed ID: 36943242
[TBL] [Abstract][Full Text] [Related]
37. Real-world routine diagnostic molecular analysis for TP53 mutational status is recommended over p53 immunohistochemistry in B-cell lymphomas.
de Haan LM; de Groen RAL; de Groot FA; Noordenbos T; van Wezel T; van Eijk R; Ruano D; Diepstra A; Koens L; Nicolae-Cristea A; Hartog WCED; Terpstra V; Ahsmann E; Dekker TJA; Sijs-Szabo A; Veelken H; Cleven AHG; Jansen PM; Vermaat JSP
Virchows Arch; 2023 Oct; ():. PubMed ID: 37851120
[TBL] [Abstract][Full Text] [Related]
38. Prospective Clinical Prognostication of Endometrial Carcinomas Based on Next-Generation Sequencing and Immunohistochemistry-Real-World Implementation and Results at a Tertiary Care Center.
Davies KD; Smith LP; Guimaraes-Young A; Corr BR; Fisher CM; Guntupalli SR; Berning AA; Post MD; Pino D; Aisner DL; Wolsky RJ
Int J Gynecol Pathol; 2023 Oct; ():. PubMed ID: 37922951
[TBL] [Abstract][Full Text] [Related]
39. Patterns of recurrence in surgically treated women for TP53-mutated endometrial carcinomas.
Pain FA; Beinse G; Azaïs H; Auvray-Kuentz M; Garcin LM; Delanoy N; Bentivegna E; Benoit L; Nguyen-Xuan HT; Blons H; Fabiano E; LE Frère Belda MA; Bats AS; Koual M
Eur J Surg Oncol; 2023 Sep; 49(9):106954. PubMed ID: 37349159
[TBL] [Abstract][Full Text] [Related]
40. Synchronous Endometrial and Ovarian Carcinomas: Pathologic and Molecular Analysis Highlights the Monoclonal Origin of the Lesions.
Guerriero A; Moro M; Angerilli V; Munari G; Santoro L; Alessandrini L; Favero L; Tasca G; Fassan M; Dei Tos AP
Int J Gynecol Pathol; 2023 Sep; ():. PubMed ID: 37922918
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
